- Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceuticals has acquired global rights to privately held Hemera Biosciences' HMR59, a one-time intravitreally injected gene therapy designed to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration.
- According to Hemera, HMR59 increases the ability of retina cells to make a soluble form of a protective protein called CD59 which protects cells from a natural inflammatory cascade called complement associated with the body's nonspecific immune response. Complement overactivity is believed to be the cause of macular degeneration.
- https://seekingalpha.com/news/3640789-j-and-j-acquires-rights-to-gene-therapy-for-vision-loss-disorder
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.